The DOI matches its Crossref record; 262 of the 262 references it cites were found in a registry or an index.
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Open accessAbstract
Vaccination represents the best line of defense against infectious diseases and is crucial in curtailing pandemic spread of emerging pathogens to which a population has limited immunity. In recent years, mRNA vaccines have been proposed as the new frontier in vaccination, owing to their facile and rapid development while providing a safer alternative to traditional vaccine technologies such as live or attenuated viruses. Recent breakthroughs in mRNA vaccination have been through formulation with lipid nanoparticles (LNPs), which provide both protection and enhanced delivery of mRNA vaccines in vivo. In this review, current paradigms and state-of-the-art in mRNA-LNP vaccine development are explored through first highlighting advantages posed by mRNA vaccines, establishing LNPs as a biocompatible delivery system, and finally exploring the use of mRNA-LNP vaccines in vivo against infectious disease towards translation to the clinic. Furthermore, we highlight the progress of mRNA-LNP vaccine candidates against COVID-19 currently in clinical trials, with the current status and approval timelines, before discussing their future outlook and challenges that need to be overcome towards establishing mRNA-LNPs as next-generation vaccines. Statement of significance With the recent success of mRNA vaccines developed by Moderna and BioNTech/Pfizer against COVID-19, mRNA technology and lipid nanoparticles (LNP) have never received more attention. This manuscript timely reviews the most advanced mRNA-LNP vaccines that have just been approved for emergency use and are in clinical trials, with a focus on the remarkable development of several COVID-19 vaccines, faster than any other vaccine in history. We aim to give a comprehensive introduction of mRNA and LNP technology to the field of biomaterials science and increase accessibility to readers with a new interest in mRNA-LNP vaccines. We also highlight current limitations and future outlook of the mRNA vaccine technology that need further efforts of biomaterials scientists to address.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–262 of 262
Use of nanoparticle concentration as a tool to understand the structural properties of colloids
Ribeiro, L. N. D. M., Couto, V. M., Fraceto, L. F., & de Paula, E. (2018) · Scientific Reports · doi:10.1038/s41598-017-18573-7 · Cited by 125
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122
Tumor vaccination using messenger RNA: prospects of a future therapy
Kreiter, S., Diken, M., Selmi, A., Türeci, Ö., & Şahin, U. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.007 · Cited by 122
Swaminathan, G., Thoryk, E. A., Cox, K. S., Meschino, S., Dubey, S. A., Vora, K. A., Celano, R., Gindy, M. E., Casimiro, D. R., & Bett, A. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.132 · Cited by 121
Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 120
Sato, Y., Kinami, Y., Hashiba, K., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.006 · Cited by 119
Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes
Bao, Y., Jin, Y., Chivukula, P., Zhang, J., Liu, Y., Liu, J., Clamme, J., Mahato, R. I., Ng, D., Ying, W., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0874-6 · Cited by 118
Garg, N. K., Tyagi, R. K., Singh, B., Sharma, G., Nirbhavane, P., Kushwah, V., Jain, S., & Katare, O. P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.061 · Cited by 116
Long-term storage of DNA-free RNA for use in vaccine studies
Jones, K. L., Drane, D., & Gowans, E. J. (2007) · BioTechniques · doi:10.2144/000112593 · Cited by 115
Sznitowska, M., Gajewska, M., Janicki, S., Radwanska, A., & Lukowski, G. (2001) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(01)00157-6 · Cited by 113
Braet, F., Wisse, E., Bomans, P. H. H., Frederik, P. M., Geerts, W. J. C., Koster, A. J., Soon, L., & Ringer, S. P. (2007) · Microscopy Research and Technique · doi:10.1002/jemt.20408 · Cited by 113
Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy
Nakamura, T., & Harashima, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.003 · Cited by 110
Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs
Li, Q., Chan, C. S., Peterson, N. C., Hanna, R. N., Alfaro, A., Allen, K. L., Wu, H., Dall’Acqua, W. F., Borrok, M. J., & Santos, J. L. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00003 · Cited by 108
Katakowski, J. A., Mukherjee, G., Wilner, S. E., Maier, K. E., Harrison, M. T., DiLorenzo, T. P., Levy, M., & Palliser, D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.175 · Cited by 105
Ross, J., & Sullivan, T. (1985) · Blood · doi:10.1182/blood.v66.5.1149.1149 · Cited by 104
Leal, L., Guardo, A. C., Morón‐López, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., van den Ham, H., Gruters, R. A., et al. (2018) · AIDS · doi:10.1097/qad.0000000000002026 · Cited by 102
Johanning, F. W., Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L. A., Pike, M. J., & Curiel, D. T. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.9.1495 · Cited by 99
Myerson, J. W., Braender, B., Mcpherson, O., Glassman, P. M., Kiseleva, R. Y., Shuvaev, V. V., Marcos-Contreras, O. A., Grady, M. E., Lee, H., Greineder, C. F., et al. (2018) · Advanced Materials · doi:10.1002/adma.201802373 · Cited by 99
Mok, K. W. C., Lam, A. M. I., & Cullis, P. R. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00059-0 · Cited by 96
Davies, N. M., Hovdal, D., Edmunds, N. J., Nordberg, P., Dahlén, A., Dabkowska, A. P., Arteta, M. Y., Rădulescu, A., Kjellman, T., Höijer, A., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.008 · Cited by 95
Katibah, G. E., Qin, Y., Sidote, D. J., Yao, J., Lambowitz, A. M., & Collins, K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412842111 · Cited by 94
mRNA: A Novel Avenue to Antibody Therapy?
Schlake, T., Thran, M., Fiedler, K., Heidenreich, R., Petsch, B., & Fotin‐Mleczek, M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.002 · Cited by 94
Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy
Thomas, S. N., Rohner, N. A., & Edwards, E. E. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-101515-014413 · Cited by 88
Vu, M. N., Kelly, H. G., Wheatley, A. K., Peng, S., Pilkington, E. H., Veldhuis, N. A., Davis, T. P., Kent, S. J., & Truong, N. P. (2020) · Small · doi:10.1002/smll.202002861 · Cited by 88
Self-citationTuning liposome composition to modulate corona formation in human serum and cellular uptake
Yang, K., Mesquita, B. S., Horvatovich, P. L., & Salvati, A. L. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.018 · Cited by 87
Zukancic, D., Suys, E. J. A., Pilkington, E. H., Algarni, A., Al-Wassiti, H. A., & Truong, N. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111068 · Cited by 83
Self-citationHeidenreich, R., Jasny, E., Kowalczyk, A., Lutz, J., Probst, J., Baumhof, P., Scheel, B., Voss, S., Kallen, K., & Fotin‐Mleczek, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29402 · Cited by 80
Stealth particles give mucus the slip
Cu, Y., & Saltzman, W. M. (2008) · Nature Materials · doi:10.1038/nmat2347 · Cited by 80
Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles
Kulkarni, J. A., Thomson, S. B., Zaifman, J., Leung, J., Wagner, P. K., Hill, A. M., Tam, Y. Y. C., Cullis, P. R., Petkau, T. L., & Leavitt, B. R. (2020) · Nanoscale · doi:10.1039/d0nr06816k · Cited by 80
Structural analysis reveals TLR7 dynamics underlying antagonism
Tojo, S., Zhang, Z., Matsui, H., Tahara, M., Ikeguchi, M., Kochi, M., Kamada, M., Shigematsu, H., Tsutsumi, A., Adachi, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19025-z · Cited by 79
Recent advances in delivery of veterinary DNA vaccines against avian pathogens
Jazayeri, S. D., & Poh, C. L. (2019) · Veterinary Research · doi:10.1186/s13567-019-0698-z · Cited by 75
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22661 · Cited by 74
Size-controlled lipid nanoparticle production using turbulent mixing to enhance oral DNA delivery
He, Z., Hu, Y., Nie, T., Tang, H., Zhu, J., Chen, K., Liu, L., Leong, K. W., Chen, Y., & Mao, H. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.09.047 · Cited by 73
Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 72
Synergistic Silencing: Combinations of Lipid-like Materials for Efficacious siRNA Delivery
Whitehead, K. A., Sahay, G., Li, G. Z., Love, K. T., Alabi, C. A., Ma, M., Zurenko, C., Querbes, W., Langer, R., & Anderson, D. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.141 · Cited by 70
Takahashi, H., Sinoda, K., & Hatta, I. (1996) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(95)00170-0 · Cited by 64
Wang, F., Xiao, W., Elbahnasawy, M. A., Bao, X., Zheng, Q., Gong, L., Zhou, Y., Yang, S., Fang, A., Farag, M. M. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00980 · Cited by 59
Sato, Y., Okabe, N., Note, Y., Hashiba, K., Maeki, M., Tokeshi, M., & Harashima, H. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.11.022 · Cited by 57
Rincón-Restrepo, M., Mayer, A. T., Hauert, S., Bonner, D. K., Phelps, E. A., Hubbell, J. A., Swartz, M. A., & Hirosue, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.047 · Cited by 55
Lipid–polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions
Garg, N. K., Tandel, N., Jadon, R. S., Tyagi, R. K., & Katare, O. P. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.033 · Cited by 52
Ziegler, A., Soldner, C., Lienenklaus, S., Spanier, J., Trittel, S., Riese, P., Kramps, T., Weiß, S., Heidenreich, R., Jasny, E., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601129 · Cited by 50
Doener, F., Hong, H. S., Meyer, I., Tadjalli-Mehr, K., Daehling, A., Heidenreich, R., Koch, S. D., Fotin-Mleczek, M., & Gnad-Vogt, U. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.024 · Cited by 48
Zhang, H., Smedt, S. C. D., & Remaut, K. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.016 · Cited by 48
Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice
Rosigkeit, S., Meng, M., Grunwitz, C. R., Gomes, P., Kreft, A., Hayduk, N., Heck, R., Pickert, G., Ziegler, K., Abassi, Y., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00370 · Cited by 48
Wang, Y., Lai, S. K., Suk, J. S., Pace, A., Cone, R. A., & Hanes, J. S. (2008) · Angewandte Chemie · doi:10.1002/ange.200803526 · Cited by 48
Lipid‐Modified Aminoglycosides for mRNA Delivery to the Liver
Yu, X., Liu, S., Cheng, Q., Wei, T., Lee, S. M., Zhang, D., & Siegwart, D. J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901487 · Cited by 47
Garg, N. K., Singh, B., Kushwah, V., Tyagi, R. K., Sharma, R. K., Jain, S., & Katare, O. P. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.05.008 · Cited by 41
Targeting immune cells within lymph nodes
Porter, C. J. H., & Trevaskis, N. L. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0663-z · Cited by 41
Self-citationWilks, A. B., Christian, E., Seaman, M. S., Sircar, P., Carville, A., Gómez, C. E., Estéban, M., Pantaleo, G., Barouch, D. H., Letvin, N. L., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002751 · Cited by 36
RNA pulsed dendritic cells: An approach for cancer immunotherapy
Garg, N. K., Dwivedi, P., Prabha, P. S., & Tyagi, R. K. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.027 · Cited by 35
Childhood immunisation: what is the future?
Pollard, A. J. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.095760 · Cited by 35
Phua, K. K. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/680620 · Cited by 35
Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery
Jeong, S., Jang, J.-H., Cho, H., & Lee, Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1060-0 · Cited by 34
Vu, M. N., Kelly, H. G., Tan, H., Juno, J. A., Esterbauer, R., Davis, T. P., Truong, N. P., Wheatley, A. K., & Kent, S. J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002142 · Cited by 34
Self-citationAllison, S. J., & Milner, J. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.68 · Cited by 31
Imam, Z. I., Kenyon, L. E., Ashby, G., Nagib, F., Mendicino, M., Zhao, C., Gadok, A. K., & Stachowiak, J. C. (2017) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-017-0489-4 · Cited by 31
Edward Jenner's Inquiry after 200 years
Baxby, D. (1999) · BMJ · doi:10.1136/bmj.318.7180.390 · Cited by 25
Combined vaccines for prophylaxis of infectious conditions
Shende, P. K., & Waghchaure, M. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1576709 · Cited by 21
Chaudhari, R. H., Tandel, N., Sahu, K., Negi, S., Bashir, H., Rupareliya, A., Mishra, R. P. N., Dalai, S. K., & Tyagi, R. K. (2021) · Nanomaterials · doi:10.3390/nano11020406 · Cited by 21
Imam, Z. I., Kenyon, L. E., Ashby, G., Nagib, F., Mendicino, M., Zhao, C., Gadok, A. K., & Stachowiak, J. C. (2017) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-017-0491-x · Cited by 18
A DNA telomerase vaccine for canine cancer immunotherapy
Thalmensi, J., Pliquet, É., Liard, C., Chamel, G., Rogez‐Kreuz, C., Bestetti, T., Escande, M. C., Kostrzak, A., Jimenez, A., Bourges, E., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26927 · Cited by 18
Thielmann, A., Puth, M., & Weltermann, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225764 · Cited by 15
Cited by
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine
Ju, Y., Lee, W. S., Pilkington, E. H., Kelly, H. G., Li, S., Selva, K. J., Wragg, K. M., Subbarao, K., Nguyen, T. H. O., Rowntree, L. C., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04543 · Cited by 372
Self-citationPEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Kiaie, S. H., Majidi Zolbanin, N., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 255
Toxoplasmosis vaccines: what we have and where to go?
Zhang, Y., Li, D., Lu, S., & Zheng, B. (2022) · npj Vaccines · doi:10.1038/s41541-022-00563-0 · Cited by 77
Metadata
- Authors
- Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., & Truong, N. P.
- Venue
- Acta Biomaterialia
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 131
- Pages
- 16-40
- ISSN
- 1742-7061 (ISSN-L)
- OpenAlex
- W3176098210
- Cited by
- 260
- References
- 262
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.